Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài:"High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial. | Mahajan et al. Respiratory Research 2011 12 120 http content 12 1 120 RESPIRATORY RESEARCH RESEARCH Open Access High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations a randomized sham-controlled clinical trial 1 2 34 22 2 Amit K Mahajan Gregory B Diette Umur Hatipoglu Andrew Bilderback Alana Ridge Vanessa Walker Harris Vijay Dalapathi1 Sameer Badlani5 Stephanie Lewis6 Jeff T Charbeneau6 Edward T Naureckas1 and Jerry A Krishnan6 Abstract Background High frequency chest wall oscillation HFCWO is used for airway mucus clearance. The objective of this study was to evaluate the use of HFCWO early in the treatment of adults hospitalized for acute asthma or chronic obstructive pulmonary disease COPD . Methods Randomized multi-center double-masked phase II clinical trial of active or sham treatment initiated within 24 hours of hospital admission for acute asthma or COPD at four academic medical centers. Patients received active or sham treatment for 15 minutes three times a day for four treatments. Medical management was standardized across groups. The primary outcomes were patient adherence to therapy after four treatments minutes used 60 minutes prescribed and satisfaction. Secondary outcomes included change in Borg dyspnea score 1 unit indicates a clinically significant change spontaneously expectorated sputum volume and forced expired volume in 1 second. Results Fifty-two participants were randomized to active n 25 or sham n 27 treatment. Patient adherence was similarly high in both groups 91 vs. 93 p . Patient satisfaction was also similarly high in both groups. After four treatments a higher proportion of patients in the active treatment group had a clinically significant improvement in dyspnea vs. p . There were no significant differences in other secondary outcomes. Conclusions HFCWO is well tolerated in adults hospitalized for acute asthma or COPD and significantly .
